Evidence map›Paper›PMID 36786675›Full record

ArticleMolecular oncology2023

Targeting protein folding in N-Myc-driven medulloblastoma.

Gintvile Valinciute, Martine F Roussel

Abstract read
In one paragraph

Article in Molecular oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Gintvile ValinciuteDepartment of Tumor Cell Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID 0000-0003-0680-3026
Martine F RousselDepartment of Tumor Cell Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.

Funding

The DNA Damage Response and Tumorigenesis in the BrainP01CA096832 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI BAKER, SUZANNE J. · 2003 to 2025
$38.0M
NCI NIH HHS P01 CA096832
6 · The paper itself

Abstract

Selective targeting of N-Myc-driven Sonic hedgehog (SHH) medulloblastoma has been a challenge for many years and, despite decades of research, few targeted therapy opportunities exist. Recently, Kuzuoglu-Ozturk et al. characterized the translatome of N-Myc-driven medulloblastoma as a promising therapeutic target. The study showed that N-Myc controls a subset of members of the protein folding machinery that could be inhibited pharmacologically and validated a subset of Hsp70 functions as required for medulloblastoma progression in vitro and in vivo.

Indexed as

Cerebellar NeoplasmsMedulloblastomaHedgehog ProteinsHumansN-Myc Proto-Oncogene ProteinProtein FoldingSignal TransductionHedgehog ProteinsN-Myc Proto-Oncogene ProteinchaperonesEIF4EHsp70medulloblastomaN-Mycprotein translation

Identifiers

PMID36786675
PMCPMC9980298

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.